Baird Maintains Outperform on Maravai LifeSciences, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Schulte maintains an Outperform rating on Maravai LifeSciences (MRVI) and raises the price target from $8 to $10.
May 09, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Catherine Schulte maintains an Outperform rating on Maravai LifeSciences and raises the price target from $8 to $10.
The upgrade in the price target by Baird reflects a positive outlook on Maravai LifeSciences, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100